The estimated Net Worth of George Georgiou is at least 2.11 百万$ dollars as of 13 August 2018. George Georgiou owns over 37,333 units of Aeglea BioTherapeutics Inc stock worth over 2,112,091$ and over the last 8 years George sold AGLE stock worth over 0$.
George has made over 1 trades of the Aeglea BioTherapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently George exercised 37,333 units of AGLE stock worth 220,638$ on 13 August 2018.
The largest trade George's ever made was exercising 37,333 units of Aeglea BioTherapeutics Inc stock on 13 August 2018 worth over 220,638$. On average, George trades about 9,333 units every 0 days since 2016. As of 13 August 2018 George still owns at least 175,861 units of Aeglea BioTherapeutics Inc stock.
You can see the complete history of George Georgiou stock trades at the bottom of the page.
George's mailing address filed with the SEC is C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN, TX, 78746.
Over the last 8 years, insiders at Aeglea BioTherapeutics Inc have traded over 1,425,674$ worth of Aeglea BioTherapeutics Inc stock and bought 1,931,829 units worth 12,152,489$ . The most active insiders traders include Bros. Advisors Lp667, L.P.B...、Bioventures Ltd Novartis Ag...、Advisors Llc Orbi Med Capit.... On average, Aeglea BioTherapeutics Inc executives and independent directors trade stock every 70 days with the average trade being worth of 864,564$. The most recent stock trade was executed by Marcio Souza on 25 August 2022, trading 90,000 units of AGLE stock currently worth 50,400$.
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
Aeglea BioTherapeutics Inc executives and other stock owners filed with the SEC include: